John Armitage
Egerton Capital
John Armitage Gilead Sciences Inc stake
total: 222
Egerton Capital GILD trades
- Total transactions:
- 10
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 5
- Held since:
- 2014 Q2
- Held for:
- 9 quarters
- Latest activity:
- 2016 Q3
According to 2026 Q2 report, John Armitage doesn't hold any Gilead Sciences Inc (GILD) shares. To date, the estimated cost basis is nearly $95.08 for "buy" trades and estimated average "sell" price is $91.3. Egerton Capital first purchased GILD in 2014 Q2, initially acquiring about 6.15M shares. Since the initial investment in Gilead Sciences Inc (GILD), Egerton Capital has made 9 more transactions.
When did John Armitage sell Gilead Sciences Inc (GILD)?
John Armitage sold off the entire Gilead Sciences Inc (GILD) position in 2016 Q3.
When did John Armitage buy Gilead Sciences Inc (GILD)?
John Armitage first invested in Gilead Sciences Inc (GILD) in 2014 Q2 at the reported quarter-end price of $82.91 per share.
What's the cost basis of Egerton Capital's GILD stake?
The estimated cost basis for Gilead Sciences Inc (GILD) stake is around $95.08 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $95.08
- Weighted AVG sell price:
- $91.30
John Armitage's historical trades in Gilead Sciences Inc
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2016 Q3
|
0.00%
|
$83.42
|
-100% (-1,397,732)
|
|||
|
2016 Q2
|
1.31%
|
$83.42
|
-69.09% (-3,123,953)
|
|||
|
2016 Q1
|
3.96%
|
$91.86
|
+5.36% (+230,218)
|
|||
|
2015 Q4
|
4.50%
|
$101.19
|
-23.24% (-1,299,329)
|
|||
|
2015 Q3
|
6.20%
|
$98.19
|
+39.79% (+1,591,342)
|
|||
|
2015 Q2
|
5.93%
|
$117.08
|
+406.01% (+3,209,057)
|
|||
|
2015 Q1
|
1.06%
|
$98.13
|
-31.67% (-366,367)
|
|||
|
2014 Q4
|
1.46%
|
$94.26
|
-79.70% (-4,542,556)
|
|||
|
2014 Q3
|
8.16%
|
$106.45
|
-7.31% (-449,423)
|
|||
|
2014 Q2
|
8.07%
|
$82.91
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.